Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes

Renee G. C. Maas; Soah Lee; Magdalena Harakalova; Christian J. B. Snijders Blok; William R. Goodyer; Jesper Hjortnaes; Pieter A. F. M. Doevendans; Linda W. van Laake; Jolanda van der Velden; Folkert W. Asselbergs; Joseph C. Wu; Joost P. G. Sluijter; Sean M. Wu; Jan W. Buikema

doi:10.1016/j.xpro.2021.100334

Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes

Renee G. C. Maas
, Soah Lee
, Magdalena Harakalova
, Christian J. B. Snijders Blok
, William R. Goodyer
, Jesper Hjortnaes
, Pieter A. F. M. Doevendans
, Linda W. van Laake
, Jolanda van der Velden
, Folkert W. Asselbergs
, Joseph C. Wu
, Joost P. G. Sluijter
, Sean M. Wu^*
, Jan W. Buikema^*

^*Corresponding author for this work

University Medical Center Utrecht
Stanford University
Leiden University Medical Center
Amsterdam UMC, Department of Physiology, Amsterdam Cardiovascular Science, Amsterdam, Netherlands
Amsterdam UMC - Vrije Universiteit Amsterdam
University College London

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Since the discovery of human induced pluripotent stem cells (hiPSCs), numerous strategies have been established to efficiently derive cardiomyocytes from hiPSCs (hiPSC-CMs). Here, we describe a cost-effective strategy for the subsequent massive expansion (>250-fold) of high-purity hiPSC-CMs relying on two aspects: removal of cell-cell contacts and small-molecule inhibition with CHIR99021. The protocol maintains CM functionality, allows cryopreservation, and the cells can be used in downstream assays such as disease modeling, drug and toxicity screening, and cell therapy. For complete details on the use and execution of this protocol, please refer to Buikema (2020).

Original language	English
Article number	100334
Journal	STAR Protocols
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/j.xpro.2021.100334
Publication status	Published - 19 Mar 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.xpro.2021.100334

Cite this

Maas, R. G. C., Lee, S., Harakalova, M., Snijders Blok, C. J. B., Goodyer, W. R., Hjortnaes, J., Doevendans, P. A. F. M., van Laake, L. W., van der Velden, J., Asselbergs, F. W., Wu, J. C., Sluijter, J. P. G., Wu, S. M., & Buikema, J. W. (2021). Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes. STAR Protocols, 2(1), Article 100334. https://doi.org/10.1016/j.xpro.2021.100334

@article{a16ba26bb0a54de2ad30844ea25467f8,

title = "Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes",

abstract = "Since the discovery of human induced pluripotent stem cells (hiPSCs), numerous strategies have been established to efficiently derive cardiomyocytes from hiPSCs (hiPSC-CMs). Here, we describe a cost-effective strategy for the subsequent massive expansion (>250-fold) of high-purity hiPSC-CMs relying on two aspects: removal of cell-cell contacts and small-molecule inhibition with CHIR99021. The protocol maintains CM functionality, allows cryopreservation, and the cells can be used in downstream assays such as disease modeling, drug and toxicity screening, and cell therapy. For complete details on the use and execution of this protocol, please refer to Buikema (2020).",

author = "Maas, \{Renee G. C.\} and Soah Lee and Magdalena Harakalova and \{Snijders Blok\}, \{Christian J. B.\} and Goodyer, \{William R.\} and Jesper Hjortnaes and Doevendans, \{Pieter A. F. M.\} and \{van Laake\}, \{Linda W.\} and \{van der Velden\}, Jolanda and Asselbergs, \{Folkert W.\} and Wu, \{Joseph C.\} and Sluijter, \{Joost P. G.\} and Wu, \{Sean M.\} and Buikema, \{Jan W.\}",

year = "2021",

month = mar,

day = "19",

doi = "10.1016/j.xpro.2021.100334",

language = "English",

volume = "2",

journal = "STAR Protocols",

issn = "2666-1667",

publisher = "Cell Press",

number = "1",

}

Maas, RGC, Lee, S, Harakalova, M, Snijders Blok, CJB, Goodyer, WR, Hjortnaes, J, Doevendans, PAFM, van Laake, LW, van der Velden, J, Asselbergs, FW, Wu, JC, Sluijter, JPG, Wu, SM & Buikema, JW 2021, 'Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes', STAR Protocols, vol. 2, no. 1, 100334. https://doi.org/10.1016/j.xpro.2021.100334

TY - JOUR

T1 - Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes

AU - Maas, Renee G. C.

AU - Lee, Soah

AU - Harakalova, Magdalena

AU - Snijders Blok, Christian J. B.

AU - Goodyer, William R.

AU - Hjortnaes, Jesper

AU - Doevendans, Pieter A. F. M.

AU - van Laake, Linda W.

AU - van der Velden, Jolanda

AU - Asselbergs, Folkert W.

AU - Wu, Joseph C.

AU - Sluijter, Joost P. G.

AU - Wu, Sean M.

AU - Buikema, Jan W.

PY - 2021/3/19

Y1 - 2021/3/19

N2 - Since the discovery of human induced pluripotent stem cells (hiPSCs), numerous strategies have been established to efficiently derive cardiomyocytes from hiPSCs (hiPSC-CMs). Here, we describe a cost-effective strategy for the subsequent massive expansion (>250-fold) of high-purity hiPSC-CMs relying on two aspects: removal of cell-cell contacts and small-molecule inhibition with CHIR99021. The protocol maintains CM functionality, allows cryopreservation, and the cells can be used in downstream assays such as disease modeling, drug and toxicity screening, and cell therapy. For complete details on the use and execution of this protocol, please refer to Buikema (2020).

AB - Since the discovery of human induced pluripotent stem cells (hiPSCs), numerous strategies have been established to efficiently derive cardiomyocytes from hiPSCs (hiPSC-CMs). Here, we describe a cost-effective strategy for the subsequent massive expansion (>250-fold) of high-purity hiPSC-CMs relying on two aspects: removal of cell-cell contacts and small-molecule inhibition with CHIR99021. The protocol maintains CM functionality, allows cryopreservation, and the cells can be used in downstream assays such as disease modeling, drug and toxicity screening, and cell therapy. For complete details on the use and execution of this protocol, please refer to Buikema (2020).

UR - https://www.scopus.com/pages/publications/85118528761

UR - https://www.ncbi.nlm.nih.gov/pubmed/33615277

U2 - 10.1016/j.xpro.2021.100334

DO - 10.1016/j.xpro.2021.100334

M3 - Article

C2 - 33615277

SN - 2666-1667

VL - 2

JO - STAR Protocols

JF - STAR Protocols

IS - 1

M1 - 100334

ER -

Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this